GlassScriptPhysician profile
May Galbreath
NPI 1336424878
$2,487.84
in general payments reported to CMS, 2019-2025
18 companies · $59.99 in 2025
The $59.99 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $877 · 2023: $962 · 2024: $375 · 2025: $59.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $513.48 | 2021-2024 | |
| Alkermes, INC. | $505.53 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $286.55 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $217.14 | 2021-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $168.05 | 2022-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $157.41 | 2021-2022 | |
| Lundbeck LLC | $102.86 | 2022-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $97.91 | 2021-2023 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $97.82 | 2023-2024 | Auvelity |
| Novo Nordisk INC | $59.99 | 2025 | |
| Janssen Pharmaceuticals, INC | $52.62 | 2022-2023 | Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $47.81 | 2023-2024 | Trintellix |
| Bausch Health US, LLC | $43.94 | 2023-2024 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $39.82 | 2023 | Austedo |
| Noven Therapeutics, LLC | $37.70 | 2024 | Secuado, Xelstrym |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $22.91 | 2023 | Jornay Pm |
| Tris Pharma INC | $19.45 | 2023 | Dyanavel Xr |
| Avion Pharmaceuticals | $16.85 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Galbreath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.